Cargando…
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Gene therapy strategies for congenital myopathies may require repeat administration of adeno-associated viral (AAV) vectors due to aspects of the clinical application, such as: (i) administration of doses below therapeutic efficacy in patients enrolled in early phase clinical trials; (ii) progressiv...
Autores principales: | Corti, M, Elder, ME, Falk, DJ, Lawson, L, Smith, BK, Nayak, S, Conlon, TJ, Clément, N, Erger, K, Lavassani, E, Green, MM, Doerfler, PA, Herzog, RW, Byrne, BJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275004/ https://www.ncbi.nlm.nih.gov/pubmed/25541616 http://dx.doi.org/10.1038/mtm.2014.33 |
Ejemplares similares
-
Advancements in AAV-mediated Gene Therapy for Pompe Disease
por: Salabarria, S.M., et al.
Publicado: (2020) -
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
por: Hui, Daniel J, et al.
Publicado: (2015) -
Tailoring the AAV2 capsid vector for bone-targeting
por: Alméciga-Díaz, Carlos J., et al.
Publicado: (2018) -
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019) -
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
por: Gehrke, Miranda, et al.
Publicado: (2022)